Archives
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-10-05
Saito and colleagues established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids retained differentiation capacity and produced intestinal epithelial cells with reported cytochrome P450 and transporter activities, supporting their evaluation as a human-relevant model for oral drug absorption and metabolism.
-
CX-5461 in Cervical Cancer: Mitotic Catastrophe
2026-10-05
A 2026 Biochemical Pharmacology study identifies DNA damage, dysregulated mitotic entry, and mitotic catastrophe as central features of CX-5461 activity in cervical cancer cell models. The findings also support further evaluation of CX-5461 as a cisplatin-sensitizing RNA polymerase I inhibitor, while remaining preclinical and dependent on validation across tumor and treatment contexts.
-
Angiotensin III: RAAS Biology and Emerging Evidence
2026-10-04
Angiotensin III is a renin–angiotensin–aldosterone system peptide with established cardiovascular and neuroendocrine relevance and a newly reported connection to SARS-CoV-2 spike-protein binding. This overview separates catalog claims from published findings, explains the peptide’s relationship to angiotensin II, compares receptor-signaling and viral-binding evidence, and outlines conceptual research applications without treating in vitro binding results as evidence of infection or clinical risk.
-
Drying Strategies for mRNA-LNP Stability
2026-10-03
Zhen et al. review how freeze-drying and emerging drying technologies may address the storage constraints of mRNA and other nucleic acid lipid nanoparticles. The paper’s central contribution is a structure-aware comparison of drying approaches, emphasizing that stability, potency, reconstitution, and administration route must be evaluated together rather than treated as separate formulation goals.
-
LTI6426 Enhances Panobinostat in Myeloma
2026-10-02
The reference study shows that the protein disulfide isomerase inhibitor LTI6426 can substantially improve panobinostat activity in proteasome inhibitor-resistant multiple myeloma models. Its most important contribution is the identification of a low-dose combination strategy linked to ER-stress effectors ATF3, DDIT3/CHOP, and DNAJB1 as candidate pharmacodynamic biomarkers.
-
From mRNA Synthesis to Disc Repair
2026-10-01
An evidence-informed perspective on how capped, polyadenylated mRNA can support engineered fibroblast therapies for inflammatory intervertebral disc degeneration—and how translational teams can connect RNA quality, cellular potency, and clinical manufacturing strategy.
-
Combination Therapy Against Mycobacterium avium Complex
2026-10-01
The reference study combined agar-dilution susceptibility testing with intracellular macrophage assays to examine clarithromycin, temafloxacin, and ethambutol against pigmented and non-pigmented Mycobacterium avium complex isolates. Its central finding was that combination activity depended on the drug pair and bacterial phenotype, while the three-drug regimen produced the strongest intracellular bactericidal effect.
-
Cycloheximide Workflows for Protein Turnover Studies
2026-09-30
Cycloheximide provides an acute way to separate ongoing protein synthesis from protein stability, making it useful for turnover experiments, apoptosis assays, and mechanistic studies of mitochondrial stress. This guide translates the DCLRE1A–SYVN1 cataract findings into practical assay designs while emphasizing controls, optimization, and safety.
-
L-Leucine C6104 for Reliable Cell Assays
2026-09-30
A practical, scenario-based guide to using L-Leucine (SKU C6104) in cell viability, proliferation, and cytotoxicity workflows. It explains how to separate biological effects from assay interference, establish controls, interpret numeric readouts, and evaluate reagent reliability without making unsupported product-performance claims.
-
Danazol Workflows for HPG-Axis Research
2026-09-29
Use Danazol as a controlled endocrine perturbation to dissect steroidogenesis, luteinizing hormone signaling, and hypothalamic–pituitary–gonadal axis activation. This workflow translates a recent rat-model study into practical cell, tissue, and comparative-design strategies while addressing solubility, vehicle, and interpretation risks.
-
Phosphatase Inhibitor Cocktail 1: Signal Fidelity
2026-09-29
Phosphatase Inhibitor Cocktail 1 supports protein phosphorylation preservation when dynamic signaling samples are collected and lysed. This article connects its biochemical coverage to CD59–JAK2–STAT3 research and shows how assay design, controls, and handling determine phosphoproteomic reliability.
-
Amikacin Disulfate: From Ribosome to Translation
2026-09-28
A translational perspective on how Amikacin disulfate connects 16S rRNA biology, bacterial protein synthesis suppression, protein–antibiotic interactions, and reproducible antibiotic resistance research workflows.
-
Cycloheximide for Translation and Turnover Studies
2026-09-28
Cycloheximide provides a rapid way to test whether a cellular response depends on ongoing protein synthesis, complementing genetic and signaling assays rather than replacing them. This guide shows how to build cautious translation-block and protein-turnover workflows, including a clearly bounded application to NLRP3 inflammasome research.
-
Azathramycin A: Reading Macrolide Resistance Data
2026-09-26
Azathramycin A is a macrolide antibiotic and M. tuberculosis ribosome-binding research compound. This article uses recent Mycoplasma pneumoniae resistance findings to show how genotype, susceptibility measurements, and pathogen-specific limits should shape interpretation in tuberculosis research.
-
InstaBlue Protein Stain Solution: Practical Gel Workflow
2026-09-25
InstaBlue Protein Stain Solution is a ready-to-use Coomassie Brilliant Blue protein stain for rapid visualization of protein bands in polyacrylamide gels, without fixation, washing, or destaining. It is intended for gel-based protein electrophoresis analysis; do not assume compatibility with other matrix types or workflows that require solvent fixation, and validate downstream mass spectrometry procedures in your laboratory.